Form 8-K - Current report:
SEC Accession No. 0001213900-25-032584
Filing Date
2025-04-16
Accepted
2025-04-16 16:10:08
Documents
14
Period of Report
2025-04-10
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0238473-8k_abpro.htm   iXBRL 8-K 39120
  Complete submission text file 0001213900-25-032584.txt   260599

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE abp-20250410.xsd EX-101.SCH 3854
3 XBRL DEFINITION FILE abp-20250410_def.xml EX-101.DEF 26755
4 XBRL LABEL FILE abp-20250410_lab.xml EX-101.LAB 36995
5 XBRL PRESENTATION FILE abp-20250410_pre.xml EX-101.PRE 25379
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0238473-8k_abpro_htm.xml XML 5990
Mailing Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013
Business Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013 248-890-7200
Abpro Holdings, Inc. (Filer) CIK: 0001893219 (see all company filings)

EIN.: 871013956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41224 | Film No.: 25842953
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)